> top > docs > BB-kb@ldeleger:BB-kb-3074181 > annotations

BB-kb@ldeleger:BB-kb-3074181 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-ost-19-BB-kb-train

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue NCBI_Taxonomy OntoBiotope
T1 0-202 Title denotes [Experimental and clinical studies of flomoxef in the field of obstetrics and gynecology. Representative Committee Members of the Research Team for Infections in the Field of Obstetrics and Gynecology].
T2 203-1977 Paragraph denotes Flomoxef (FMOX) has a broad antibacterial spectrum against Gram-positive and Gram-negative bacteria; especially its potent antibacterial activity against Staphylococcus aureus is a significant advantage that may not be found with other cephem compounds. In our determination of its antibacterial potency against various clinical isolates obtained from clinical materials (amniotic fluid, intrauterine secretions, exudates of the pelvic dead space) of patients with various infections, we obtained results representing specific features of this drug. From the results, the drug may be expected to produce an excellent effect in the treatment of various infections. Our study on drug concentrations in body fluids and genital tissues demonstrated a good transfer of this drug into various tissues; in every tissue examined, the drug administered by the usual method in the usual dose yielded a concentration exceeding MIC for principal pathogens, thus promising a good clinical response. Indeed a high clinical efficacy rate of 90.1% (good to very good responses) was obtained in a clinical trial involving 222 cases. Administration of the drug in 2 g quantity daily produced a high response rate of 92.8%. It was especially noteworthy that a good response was obtained in 30 of 32 cases (93.8%) in which other cephem compounds had failed. In evaluation of the bacteriological effect, furthermore, the drug showed an excellent rate of bacterial elimination. In conclusion, this drug is expected to be greatly useful in the light of its good transfer into genital tissues and its strong antibacterial activities against Gram-positive cocci, Gram-negative bacteria and anaerobes as well as against multiple bacterial infections predominating among women with genital infections.
T3 262-275 Phenotype denotes Gram-positive OBT:000649
T4 280-293 Phenotype denotes Gram-negative OBT:000648
T5 357-378 Microorganism denotes Staphylococcus aureus 1280
T6 523-531 Habitat denotes clinical OBT:003220
T7 555-686 Habitat denotes clinical materials (amniotic fluid, intrauterine secretions, exudates of the pelvic dead space) of patients with various infections OBT:000039
T8 575-589 Habitat denotes amniotic fluid OBT:000485
T9 591-603 Habitat denotes intrauterine OBT:000692
T10 616-649 Habitat denotes exudates of the pelvic dead space OBT:000215
T11 632-649 Habitat denotes pelvic dead space OBT:000463
T12 654-686 Habitat denotes patients with various infections OBT:003269
T14 903-914 Habitat denotes body fluids OBT:000215
T13 903-907 Habitat denotes body OBT:000214
T16 919-934 Habitat denotes genital tissues OBT:000196
T15 919-926 Habitat denotes genital OBT:000643
T17 990-997 Habitat denotes tissues OBT:000196
T18 1008-1014 Habitat denotes tissue OBT:000196
T19 1137-1146 Phenotype denotes pathogens OBT:000375
T20 1756-1771 Habitat denotes genital tissues OBT:000196
T21 1756-1763 Habitat denotes genital OBT:000643
T22 1820-1833 Phenotype denotes Gram-positive OBT:000649
T23 1834-1839 Phenotype denotes cocci OBT:000850
T24 1841-1854 Phenotype denotes Gram-negative OBT:000648
T25 1868-1877 Phenotype denotes anaerobes OBT:000189
T26 1947-1976 Habitat denotes women with genital infections OBT:003463|OBT:003269
T27 1958-1965 Habitat denotes genital OBT:000643